655

Chimia 50 (1996) 655–660 © Neue Schweizerische Chemische Gesellschaft ISSN 0009–4293

Research Topics

Pierre Vogel*

Abstract. Quantum-mechanical calculations have been applied to predict thermodynamic and reactivity properties of unknown organic molecules, being stable compounds or reactive intermediates. Through synthesis some of the theoretical systems become real compounds that can be synthons (synthetic intermediates) or chirons (optically pure synthetic intermediates) useful in the preparation of natural products and analogues of biological interest (anti-cancer, anti-virus, antibiotic, anti-diabetes agents). Our interests concentrate on remote substituent effects as we want to play with them together with polyfunctional systems and reactions that constitute new synthetic approaches. These have to be convergent, highly stereoselective, and versatile (applicable to a large variety of derivatives: molecular diversity). We often rely on tandem reactions or/and reaction cascades. Sometimes the new compounds and their new reactions send us back to the theory and to mechanistic studies.

The Electron-Releasing Carbonyl Group and the 'Naked Sugars of the First Generation'

In 1978, we reported that 5,6-dimethylidenebicyclo[2.2.1]heptan-2-one (1) adds to methyl propynoate and methyl vinyl ketone with 'para'-regioselectivity in agreement with predictions based of frontier molecular orbital (FMO) theory [1]. A closer look at the HOMO of dienone 1 suggested that this system is capable to exchange electrons from the n orbitals of the carbonyl group with those of the homoconjugated π system through a relay σ bond [2]. Quantum calculations confirmed this hypothesis particularly by predicting that 6-oxobicyclo[2.2.1]hept-2-yl cation (2) is ca. 7 kcal/mol more stable than 5oxobicyclo[2.2.1]hept-2-yl cation (3) [3]. Further theoretical studies [4] suggested that the carbonyl group in 1 and 2 can be electron-releasing because of hyperconjugative n(CO) $\leftrightarrow \sigma \leftrightarrow \pi$ interaction that is reminiscent of the frangomeric effect discussed by Grob [5].

Although cations of type 2 and 3 may not be intermediates in electrophilic addi-

**Correspondence*: Prof. Dr. P. Vogel Section de chimie Université de Lausanne BCH CH-1015 Lausanne-Dorigny tions of bicyclo[2.2.1]hept-5-en-2-one, we predicted that these reactions would have the opposite regioselectivity than the electrophilic additions of 2-cyanobicyclo[2.2.1]hept-5-en-2-yl acetate, the synthetic precursor of bicyclo[2.2.1]hept-5en-2-one. These predictions were verified for a large variety of electrophiles and for other bicyclic olefins [6]. The concept became a useful synthetic tool when applied to optically pure 7-oxabicyclo[2.2.1]hept-5-en-2-yl derivatives such as (+)-4, (-)-5, (+)-6, and (-)-6. Indeed, in one step, electrophilic additions introduce two substituents at C(5) and C(6) of the bicyclic alkenes with high facial selectivity and high regioselectivity (e.g. 7). Reactions of the corresponding enolate with electrophilic agents introduce a third substituent at C(3) with high exo face selectivity, giving polysubstituted 7-oxanorbornanones (e.g. 8) that possess the same density of stereochemical information than a sugar such as D-glucose. A Baeyer-Villiger oxidation transforms the 7-oxanorbornanones into the corresponding uronolactones (e.g. 9) with high regioselectivity. This led us to call the optically pure systems (+)-4, (-)-5, (+)-6, and (-)-6 'naked sugars'; they are unexpensive compounds obtained from furan and 1-cyanovinyl esters [7] and represent templates that can be converted into a wide variety of enantiomerically pure compounds [8], such as rare D- or L-sugars and analogues, Cnucleosides [9], conduritols [10], conduramines [11], polyfunctional cyclopentanes (carbapentoses) [12], and natural products of biological interest [13][14].

Electrophilic additions of alkenes can also be controlled by the participation of remote substituents as illustrated with the bromine additions of acetals **10** and **11**.



CHIMIA 50 (1996) Nr. 12 (Dezember)



This feature has been exploited by us in a total, asymmetric synthesis of (+)-castanosperime, a natural glycosidase inhibitor [15]. On their side, *Cossy* and coworkers [16] have realized a short and elegant total synthesis of ethisolide based on the same principle (*Scheme 1*).

The 'naked sugar' methodology is powerful in generating long-chain carbohydrates and analogues with predictable configurations. In 1992, we reported the first syntheses of 1,5-dideoxy-1,5-iminooctitols and their one-step conversion into the corresponding 1,2,6,7,8-pentahydroxyindolizidines [17]. Among them, derivative (-)-12 which has the same configuration as that of (-)-swainsonine is a potent inhibitor of α -mannosidases but unlike the natural alkaloid, it does not inhibit β galactosidases [18].

The search for new antibiotics by fermentation technologies has produced unusual nucleosides such as mildiomycin containing a branched decose derivative, the tunicamycines, the streptovirudins, the corynetoxins, hikizimycin, the herbicidins (1), and aureonuclemycin (2) that incorporate undecose moieties within their structure. The herbicidins exhibit herbicidal and antialgal activity. Aureonuclemycin (2) is an efficient inhibitor of Xanthomonas



oryzae, a bacterium which causes rice infection. Their carbohydrate moiety is composed of 6,10-anhydro-5-deoxy- β -Darabino-L-ido-7-undeculo-(7,3-pyranose)-furanosiduronic acid, a rare longchain carbohydrate that has an unusual furano-pyrano-pyran skeleton which can be viewed as 5-C-(α -D-arabino-2-hexulopyranosyl)-5-deoxy-D-xylo-furanose. This rare sugar has been obtained via a crossaldolization between a derivative of Dglucose and a derivative of the 'naked sugar' (+)-6 [19].

Asymmetric Synthesis of Sugar Mimics

Glycosidases are key enzymes in the biosynthesis and processing of glycoproteins, which are macromolecules involved in recognition (cell-cell, host-pathogene



interactions) and control of biological mechanisms and structures. Inhibition of glycosidases may be useful for the treatment of diseases such as diabetes, cancer, viral and bacterial infections, and inflammation. The hydroxylated indolizidines such as (+)-castanospermine and (-)-



Scheme 2

Scheme 3



OMEM COOMe R COOMe 24 23 22 OMEM OMEM mCPBA 24 ΟPiv 26 25 Ar = OMEM OMEM 26 όΡiv ÓPiv 27 28

Scheme 4



657

swainsonine and simpler piperidines and pyrrolidines (azasugars, one kind of sugar mimics) are promising inhibitors; unfortunately, they often inhibit more than one enzyme in vivo. It is believed that selectivity would be increased if the azasugar would include not only the steric and charge information of the glycosyl moiety which is liberated during the glycosidase-catalyzed hydrolysis, but also that of the aglycone which it is attached to. Such inhibitors could be dideoxy-iminoalditols attached to other sugars through non-hydrolyzable links such as the aza-C-disaccharides. Systems such as 15 [20], 16 [21], and 17 [22] have been prepared from the 'naked sugars'. The same methodology has allowed one to generate the first examples of C-glycosides carbapyranoses such as 18 [23] and of C-glycosides of aminoconduritols such as 19 [24].

'Naked Sugars of the Second Generation': Asymmetric Synthesis of Polypropionate Antibiotics

Nature provides us with a number of products of biological interest containing long-chain polypropionate fragments (chain with alternating OH and Me substituents) [25]. Because of their rarity, total synthesis can, in principle, supply sufficient quantities for their pharmaceutical testing, and very importantly, for obtaining non-natural analogues. Although very efficient methods are now available to construct these systems that possess a high density of stereochemical information, we are trying to propose new and alternative approaches which exploit the high stereoselectivities of the reactions of bicyclic templates such as 7oxabicyclo[2.2.1]hept-2-yl derivatives. We have found [26] that the ZnI_2 -catalyzed Diels-Alder additions of 2,4-dimethylfuran (a inexpensive compound obtained in two steps from mesityl oxide) to 1-cyanovinyl (1R)- or (1S)-camphanate leads to high yield of optically pure adducts (+)-20 and (-)-21 ('naked sugars of the second generation'). These compounds have allowed the development of a convergent and highly stereoselective method for the preparation of long-chain polypropionate fragments containing up to eleven contiguous stereogenic centres and tertiary-alcohol moieties [27] as illustrated in Scheme 2. In this approach, the chiral auxiliaries ((1R)- or (1S)-camphanic acid) are recovered at an early stage of the synthesis, and both enantiomeric forms of the polypropionate fragments are available with the same ease.

2,4-dimethylfuran with acetaldehyde. Experiments have allowed us to transform 23 into the polypropionate fragments 25–28 (*Scheme 3*) as racemic mixtures [28].

More recently [29] we have discovered that 22 can undergo two simultaneous







Diels-Alder additions with a bis-dienophile such as diethyl (E,E)-4-oxohepta-2,5-diene-1,7-dioate. The single adduct **29** soobtained can be desymmetrized through chirality, using monoisopinocampheylborane ((+)-IpcBH₂) as hydroborating

CHIMIA 50 (1996) Nr. 12 (Dezember)

chirality, using monoisopinocampheylborane ((+)-IpcBH₂) as hydroborating agent. After oxidation of the alcohol **30**, treatment with BH₃ (Me₂S and then with NaBO₃) led to the formation of **31** selectively. We are, therefore, able to desymmetrize **29** and to carry out different chemistries with its two 7-oxabicyclo[2.2.1]heptyl systems. Future work will tell us whether these discoveries will lead us or not to a new approach to the synthesis of complicated, long-chain polypropionate fragments.

New DNA Intercalators and Topoisomerase Inhibitors

The clinical utility of the anthracycline antitumor antibiotics such as adriamycin (32) and daunomycin (33) is well demonstrated [30]. Their effectiveness, however, is restricted due to acute bone marrow toxicity, cardiotoxicity, and drug resistance development [31]. More than 2000 analogues have been synthesized and tested during the last 30 years. Among them, idarubicin (34) 4-demethoxyadriamycin (35)[32], and carminomycin (36)[33] have comparable or better *in vivo* activity than 32 and 33 at lower dose.

Simple 1,4-bis[(aminoalkyl)amino]-9,10-anthraquinones [34] such as mitoxantrone (37) [35] and iosoxantrone (38)[36] have also useful anticancer properties. These observations together with the fact that polyamines are able to inhibit cancer cell growth [37] led us to conceive a new series of anthracycline analogues (-)-39-(-)-43 bearing aminoalkyl chains through a benzyl ether link at C(6). We have also prepared the α -L-daunosaminyl derivative (-)-44 and have evaluated the ability of these new analogues to bind calf thymus DNA through interaction, and, for some of them, their ability to inhibit topoisomerisase-I-induced relaxation of circular plasmids and topoisomerase-II-induced DNA strand religation. The newly developed synthetic approach in this work has led us to propose a new synthesis of (-)-(R)-4-demethoxy-7-deoxydaunomycinone, a known precursor of idarubicin (34). While (-)-42- (-)-44 do not intercalate calf thymus DNA, (-)-39-(-)-41 do bind with DNA. Compound (-)-39 inhibits the topoisomerase-I-induced relaxation and the topoisomerase-II-induced DNA strand religation [38].

In 1979, our group [39] demonstrated that the readily available tetraene 45 can be converted through two successive Diels-Alder additions with two different dienophiles into a variety of linearly condensed polycyclic systems including racemic anthracyclinone derivatives. This concept, which is referred nowadays to combinatorial chemistry (synthesis of libraries of compounds), was patented in 1979 already [40]. The method has been applied to the synthesis of 4-demethoxydaunomycinone [41], daunomycinone [42], and 11deoxydaunomycinone [43]. 1-(Dimethoxymethyl)-2,3,5,6-tetramethylidene-7oxabicyclo[2.2.1]heptane (46), a tetraene obtained readily from furfural, has now been used as a precursor of anthracyclinone analogues bearing a carbon substituent at C(6), as required for (-)-39-(-)-44 [38]. This method involves desymmetrization through Diels-Alder additions to 1-acetylvinyl esters of type 47 derived from diacetyl and our RADO(Et)-Cl chiral auxiliary, derived itself from (R,R)tartaric acid (SADO(Et)-Cl is derived from (S,S)-tartaric acid) [45].

New Avenues for Synthesis and Theoretical Chemistry

For more than 20 years, our group has been interested in designing new polyfunctional systems such as tetraenes 45, 46, and other polyenes such as the [2.2.2]hericene (48) and the 7-oxa[2.2.1]hericene (49). These compounds have been crucial in the development of theories that explain the decreasing tandem Diels-Alder reactivity [46] exploited in our syntheses of anthracyclines and analogues. They are also ligands for transition-metal complexes [47]. Concurrent groups have used our polyenes to construct all kind of molecular devices [48]. In collaboration with Prof. J.A. Berson at Yale University, we have found that 49 can be used to generate the singlet diradical 50 (tetramethylidenebenzene), a compound of considerable theoretical interest [49].

New Reactions of Sulfur Dioxide

The cheletropic reaction $[_{\omega}2_s+_{\pi}4_s]$ of SO₂ with 1,3-dienes to give 2,5-dihydrothiophene 1,1-dioxides (sulfolenes) is known since 1914 [50]. Before our work the hetero-*Diels-Alder* addition $[_{\pi}4_s+_{\pi}2_s]$ of SO₂ to 1,3-dienes had been reported for two cases only (*ortho*-xylylene [51], and the highly reactive 1,4,5,6-tetramethyl-2,3-dimethylidenetricyclo[2.1.1.0^{5,6}]-





hexane [52]). In the presence of a suitable catalyst (CF₃COOH, BF₃(Et₂O) and below -70° , simple 1,3-dienes such as isoprene and (*E*)-piperilene undergo hetero-*Diels-Alder* additions giving the corresponding 3,6-dihydro-1,3-oxathiin 2-oxides (sultines) with high regio- and stereoselectivity [53]. We are trying to develop a new method for the creation of C–C bonds through the oxyallylation of enoxysilanes, the oxyallylating agents arising from the *Lewis*-acid (LA)-promoted heterolysis of sultines formed by the cycloaddition of 1-oxy-1,3-dienes and SO₂ (*Scheme 4*) [54].

Homoconjugated dienes can be rearranged into conjugated 1,3-dienes in the presence of SO₂ via ene reactions (*Scheme* 5). In the cases of norbornadiene (**51**) [55] and 3,3-dimethylpenta-1,4-diene (**53**) that cannot undergo ene reactions, their reactions with SO₂ give the corresponding sulfolanes **52** and **54**, respectively, resulting from homocheletropic additions in a $[_{\omega}2_{s}+_{\pi}2_{s}+_{\pi}2_{s}]$ fashion [56]. When 2,3,5,6tetramethylidenebicyclo[2.2.1]heptane (**55**) is allowed to react at -20° with SO₂, the sulfolane **56** is formed as single product. At 0°, **56** undergoes slow cyclorever-

sion into $55 + SO_2$ and then formation of the more stable sulfolene 57 resulting from the cheletropic addition of an exocyclic 1,3-diene unit. At 25°, an equilibrium constant K = [57]/[56] = 5:1 is observed. In this case, the homocheletropic addition 55 + SO₂ \rightarrow 56 is kinetically favored but thermodynamically disfavored compared with the cheletropic addition $55 + SO_2 \rightarrow 57$. In contrast, 2,3,5,6-tetramethylidene-7oxabicyclo[2.2.1]heptane (45) does not undergo the homocheletropic addition of SO_2 between -30 and $+30^\circ$. Above -10° , slow formation of sulfolene 59 is observed [55]. Work is underway in our laboratory to understand the effect described above and to find synthetic applications to the homocheletropic additions of sulfur dioxide.

This work has been supported by the Swiss National Science Foundation, the Fonds Herbette (Lausanne), F. Hoffmann-La Roche Ltd. (Basel), Ciba-Geigy Jubiläum Stiftung (Basel), du Pont de Nemours (Wilmington), Laboratoires Fournier (Dijon), the European COST D2 program (OFES, Bern), and the Ecole Polytechnique Fédérale de Lausanne. The author wishes to thank also all his coworkers for their enthousiastic contributions

CHIMIA 50 (1996) Nr. 12 (Dezember)

Received: September 30, 1996

- P.-A. Carrupt, M. Avenati, D. Quarroz, P. Vogel, *Tetrahedron Lett.* 1978, 4413.
- [2] M. Avenati, P.-A. Carrupt, D. Quarroz, P. Vogel, *Helv. Chim. Acta* **1982**, *65*, 188.
- [3] P.-A. Carrupt, P. Vogel, *Tetrahedron Lett.* **1984**, 25, 2879.
- [4] P.-A. Carrupt, P. Vogel, J. Phys. Org. Chem. 1988, 1, 287; J. Org. Chem. 1990, 55, 5696.
- [5] C.A. Grob, Angew. Chem. Int. Ed. 1976, 15, 569; W. Fischer, C.A. Grob, Helv. Chim. Acta 1978, 61, 1588; C.A. Grob, A. Waldner, ibid. 1979, 62, 1736.
- [6] P.-A. Carrupt, P. Vogel, Tetrahedron Lett.
 1982, 23, 2563; Helv. Chim. Acta 1989, 72, 1008; K.A. Black, P. Vogel, J. Org. Chem.
 1986, 51, 5341; W. Adam, E. Crämer, E.-M. Peters, K. Peters, H.G. von Schnering, Chem. Ber. 1987, 120, 705; D. Fattori, S. Henry, P. Vogel, Tetrahedron Lett. 1993, 49, 1649; M. Lajunen, Acc. Chem. Res. 1985, 18, 254.
- [7] E. Vieira, P. Vogel, *Helv. Chim. Acta* 1983, 66, 1865; J.-L. Reymond, P. Vogel, *Tetrahedron: Asymmetry* 1990, *1*, 729; see also:
 R. Saf, K. Faber, G. Penn, H. Griengl, *Tetrahedron* 1988, 44, 389; B. Ronan, H.B. Kagan, *Tetrahedron: Asymmetry*. 1991, 2, 75; E.J. Corey, T.-P. Loh, *Tetrahedron Lett.* 1993, 34, 3979.
- [8] See e.g.: P. Vogel, D. Fattori, F. Gasparini, C. Le Drian, Synlett 1990, 173; E. de Guchteneere, D. Fattori, P. Vogel, Tetrahedron 1992, 48, 10603; P. Hünnenberger, S. Allemann, P. Vogel, Carbohydr. Res. 1994, 257, 175; F. Emery, P. Vogel, Carbohydr. Chem. 1994, 13, 555.
- [9] F. Gasparini, P. Vogel, J. Org. Chem. 1990, 55, 2451; P. Péchy, F. Gasparini, P. Vogel, Synlett 1992, 8, 676; V. Jeanneret, F. Gasparini, P. Péchy, P. Vogel, Tetrahedron 1992, 48, 10637.
- [10] C. Le Drian, E. Vieira, P. Vogel, *Helv. Chim. Acta* 1989, 72, 338; C. Le Drian, J.-P. Vionnet, P. Vogel, *ibid.* 1990, 73, 161.
- [11] S. Allemann, P. Vogel, *Helv. Chim. Acta* 1994, 77, 1.
- [12] C. Le Drian, P. Vogel, *Helv. Chim. Acta* 1987, 70, 1703.
- [13] E.g.; A. Warm, P. Vogel, *Helv. Chim. Acta* 1987, 70, 690; Y. Auberson, P. Vogel, *Tetrahedron* 1990, 46, 7019; V. Moritz, P. Vogel, *Tetrahedron Lett.* 1992, 33, 5243; J.-M. Durgnat, P. Vogel, *Helv. Chim. Acta* 1993, 76, 222; A. Baudat, P. Vogel, *ibid.* 1994, 77, 1500.
- [14] For further applications, see e.g.: O. Arjona, A. de Dios, R. Fernandéz de la Pradilla, J. Plumet, *Tetrahedron Lett.* 1991, 32, 7309;
 P. Renaud, J.-P. Vionnet, *Helv. Chim. Acta* 1993, 58, 2490; O. Arjona, A. Martin-Domenech, J. Plumet, J. Org. Chem. 1993, 58, 7929; J.-P. Vionnet, P. Renaud, *Helv. Chim. Acta* 1994, 77, 1781.
- [15] J.-L. Reymond, A.A. Pinkerton, P. Vogel, J. Org. Chem. 1991, 56, 2128.
- [16] J. Cossy, J.-L. Ranaivosata, V. Béllosta, *Tetrahedron Lett.* 1994, 35, 1205.
- [17] Y. Chen, P. Vogel, J. Org. Chem. 1994, 59, 2487.
- [18] S. Picasso, Y. Chen, P. Vogel, Carbohydr. Lett. 1994, 1, 1.

- [19] F. Emery, P. Vogel, J. Org. Chem. 1995, 60, 5843.
- [20] A. Baudat, P. Vogel, *Tetrahedron Lett.* 1996, 37, 483.
- [21] E. Frérot, C. Marquis, P. Vogel, *Tetrahe*dron Lett. **1996**, 37, 2023.
- [22] K. Kraehenbuehl, P. Vogel, Second Euro-Conference on Carbohydrate Mimics, Lago de Garda, Italy, July 16–19, 1996.
- [23] J. Cossy, J.-L. Ranaivosata, V. Béllosta, J. Ancerewicz, R. Ferritto, P. Vogel, J. Org. Chem. 1995, 60, 8351.
- [24] R. Ferritto, P. Vogel, Synlett 1996, 281.
- [25] See e.g.: R.D. Norcross, I. Paterson, Chem. Rev. 1995, 95, 2041; ref. 2 in ref. 27.
- [26] A.-F. Sevin, P. Vogel, J. Org. Chem. 1994, 59, 5920; P. Vogel, A.-F. Sevin, P. Kernen, M. Bialecki, Pure Appl. Chem. 1996, 68, 719.
- [27] P. Kernen, P. Vogel, Helv. Chim. Acta 1995, 78, 301.
- [28] J. Ancerewicz, P. Vogel, *Helv. Chim. Acta* 1996, 37, 4149.
- [29] C. Marchionni, P. Vogel, P. Roversi, Tetrahedron Lett. 1996, 37, 4149.
- [30] See e.g.: a) J. W. Lown, Chem. Soc. Rev. 1993, 165; W. Priebe, Antracycline Antibiotics: New Analogues, Method of Delivery, and Mechanisms of Action; ACS Symposium Series 574; American Chemical Society: ACS, Washington, DC, 1995; b) R.B. Weiss, Semin. Oncol. 1992, 19, 670.
- [31] L. Lenaz, J.A. Mage, *Cancer Treat. Rep.* 1976, 3, 111; D.D. VanHoff, M. Layard, M. Rosencweiz, F M. Muggia, *ibid.* 1977, 61, 1411; W.T. Beck, *Biochem. Pharma*col. 1987, 36, 2879; H.G. Keizer, H.M. Pinedo, G.J. Schuurhuis, H. Joenje, *Phar*macol. Ther. 1990, 47, 219.
- [32] See e.g.: F. Arcamone, Lloydia 1977, 40, 45; S. Neidle, Nature (London) 1977, 268, 195; F. Formelli, A.A. Casazza, Drugs Exp. Clin. Res. 1984, 10, 75; B. Barbieri, O. Bellini, G. Savi, C. Bertazzoli, S. Penco, A.M. Casazza, *ibid.* 1984, 10, 85; T. Matsumoto, M. Ohsaki, M. Suzuki, Y. Kimura, S. Terashima, Chem. Pharm. Bull. 1986, 34, 4613; N. Adams, C. Blake, M. J. Broadhurst, D.J. Bushnell, C.H. Hassall, H.R. Hartmann, E. Keech, A.R. Stratton, G.J. Thomas, J. Med. Chem. 1990, 33, 2375.
- [33] G.F. Gause, M.G. Brazhnikova, V.A. Shorin, *Cancer Chemother. Rep., Part 1* 1974, 58, 255.
- [34] K.C. Murdock, R.G. Child, P.F. Fabio, R.B. Angier, R. E. Wallace, F.E. Durr, R.V. Citarella, J. Med. Chem. 1979, 22, 1024.
- [35] See e.g.: H.D.H. Showalter, J.L. Johnson, J.M. Hoftiezer, W.R. Tumer, L.M. Werbel, W. R. Leopold, J. L. Shillis, R. C. Jackson, E. F. Elslager, J. Med. Chem. 1987, 30, 121.
- [36] See e.g.: H.D.H. Showalter, J.L. Johnson, L.M. Weiberl, W.R. Leopold, R.C. Jackson, E.F. Elslager, J. Med. Chem. 1984, 27, 255; L.-H. Zhang, W.E. Meier, E.J. Watson, E. P. Gibson, Tetrahedron Lett. 1994, 35, 3675.
- [37] See e.g.: R.J. Bergeron, J.S. McManis, W.R. Weimar, K.M. Schreier, F. Gao, Q. Wu, J. Ortiz-Ocasio, G.R. Luchetta, C. Porter, J.R.T. Vinson, J. Med. Chem. 1995, 38, 2278.

- [38] Z. Dienes, P. Vogel, Bioorg. Med. Chem. Lett. 1995, 5, 547; J. Org. Chem. 1996, 61, 6958.
- [39] P.-A. Carrupt, P. Vogel, *Tetrahedron Lett.* 1979, 20, 4533.
- [40] P. Vogel, P.-A. Carrupt, Swiss Patent application 'Polycyclic Compounds and Process for the Preparation thereof'. – Ref. RAN 4060/100, 1979
- [41] Y. Bessière, P. Vogel, *Helv. Chim. Acta* 1980, 63, 232.
- [42] J. Tamariz, P. Vogel, Angew. Chem. Int. Ed. 1984, 23, 74.
- [43] J.-M. Tornare, P. Vogel, *Helv. Chim. Acta* 1985, 68, 1069.
- [44] J.-L. Métral, J. Lauterwein, P. Vogel, Helv. Chim. Acta 1986, 69, 1287.
- [45] J.-L. Reymond, P. Vogel, *Tetrahedron:* Asymmetry **1990**, *1*, 729.
- [46] P. Vogel 'Advances in Theoretically Interesting Molecules' Ed. R.P. Thummel, JAI Press, Inc., Greenwich, CT, USA, 1989, Vol. 1, p. 201.
- [47] See e.g.: P. Vogel, R. Roulet in, 'Organometallics in Organic Synthesis 2', Eds. H. Werner and G. Erker, Springer Verlag, Berlin, 1989, p. 79–107; F. Claret, P. Vogel, Organometallics 1990, 9; E. Bonfantini, P. Vogel, J. Chem. Soc., Chem. Commun. 1991, 1334; E. Bonfantini, P. Vogel, A. Marin, A. A. Pinkerton, Bull. Soc. Chim. Fr. 1992, 129, 632.
- [48] See e.g.: P.R. Ashton, G.R. Brown, N.S. Isaacs, D. Giuffrida, F.H. Kohnke, J.P. Mathias, A.M. Z. Slawin, D. R. Smith, J.F. Stoddart, D.J. Williams, *J. Am. Chem. Soc.* **1992**, *114*, 6330; H.-Y. Zhang, A. Blaskó, J.-Q. Yu, T.C. Bruice, *ibid.* **1992**, *104*, 6621.
- [49] J.A. Reynolds, J.A. Berson, K.K. Kumashiro, J.C. Duchamp, K.W. Zilm, J.C. Scaiano, A. B. Berinstain, A. Rubello, P. Vogel, J. Am. Chem. Soc. 1993, 115, 8073.
- [50] G. de Bruin, Proc. K. Ned. Akad. Wet. 1914, 17, 585.
- [51] T. Durst, L. Tréteault-Ryan, *Tetrahedron Lett.* 1978, 2353.
- [52] R.F. Heldeweg, H. Hogeveen, J. Am. Chem. Soc. 1976, 98, 2341.
- [53] B. Deguin, P. Vogel, J. Am. Chem. Soc.
 1992, 114, 9210; B. Deguin, P. Vogel, Tetrahedron Lett. 1993, 34, 6269.
- [54] B. Deguin, J.-M. Roulet, P. Vogel, in prep. [55] O. De Lucchi, V. Lucchini, J. Chem. Soc.,
- *Chem. Commun.* **1982**, 1105.
- [56] J.-M. Roulet, B. Deguin, P. Vogel, J. Am. Chem. Soc. 1994, 116, 3639; J.-M. Roulet, P. Vogel, F. Wiesemann, A.A. Pinkerton, Tetrahedron 1995, 51, 1685.

CHIMIA 50 (1996) Nr. 12 (Dezember)